title: Effectiveness and serotype coverage: key criteria for pneumococcal vaccines for adults.
authors.affiliation: Medical Affairs & Policy, Merck Vaccines, West Point, PA 19426, USA. john_grabenstein@merck.com
authors.forename: John D
authors.initials: JD
authors.lastname: Grabenstein
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000382:microbiology* / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification* / Q000276:immunology* / Q000302:isolation & purification
chemical_list: C538862:13-valent pneumococcal vaccine; C414006:23-valent pneumococcal capsular polysaccharide vaccine; D022242:Pneumococcal Vaccines